Escherichia coli Specific Neutra™ Antibody Products

Are you struggling with prolonged drug discovery timelines, inconsistent bacterial detection, or challenges in developing high-specificity antibodies against Escherichia coli? Creative Biolabs' E. coli specific Neutra™ antibody products leverage advanced recombinant antibody engineering and high-throughput epitope mapping to deliver ultra-sensitive, validated antibodies that streamline therapeutic design, enhance diagnostic accuracy, and empower robust functional studies of E. coli virulence mechanisms.

Introduction to Escherichia coli

Escherichia coli (E. coli), a gram-negative, facultative anaerobic bacterium, is a ubiquitous member of the Enterobacteriaceae family. While most strains are commensal in the human gut, pathogenic variants—such as enterotoxigenic (ETEC), enterohemorrhagic (EHEC), and uropathogenic (UPEC)—cause diverse diseases through virulence factors like adhesins, toxins, and invasins. Its rapid replication rate (20–30 minutes/generation) and genetic plasticity make it a model organism in molecular biology and a critical target for therapeutic and diagnostic innovation.

• Structural Features

The E. coli cell envelope comprises an outer membrane containing lipopolysaccharides (LPS) with O-antigen variability, a peptidoglycan layer, and an inner cytoplasmic membrane. Surface structures like flagella (H-antigen), pili, and secretion systems (e.g., Type III) mediate motility, host adhesion, and toxin delivery. The outer membrane's porins regulate solute permeability, while LPS triggers innate immune responses via Toll-like receptor 4 (TLR4). Structural studies using cryo-EM have resolved conformational epitopes critical for antibody neutralization of key virulence proteins.

Fig.1 E. coli adhesins and harboring/motile structures.^1,3

• Pathogenicity and Immune Evasion

Pathogenic E. coli strains activate host signaling cascades such as NF-κB (via LPS-TLR4 interactions) and MAPK pathways, driving pro-inflammatory cytokine release. Shiga toxin-producing E. coli (STEC) disrupts ribosomal function via RNA N-glycosidase activity, while UPEC manipulates bladder epithelial signaling to evade immune clearance. These mechanisms underscore the need for antibodies targeting both surface antigens (e.g., O157:H7 LPS) and secreted toxins (e.g., heat-labile enterotoxin).

Fig.2 Complement evasion strategies of E. coli .^2,3

• Associated Diseases

E. coli infections manifest as gastroenteritis, hemorrhagic colitis, hemolytic uremic syndrome (HUS), urinary tract infections (UTIs), and sepsis. Antibiotic resistance in multidrug-resistant strains (e.g., ESBL-producing E. coli) amplifies clinical urgency, driving demand for antibody-based therapeutics and rapid diagnostics.

Applications of Anti-E. coli Neutralizing Antibodies

• Precision Diagnostics

Anti-E. coli antibodies enable rapid detection of pathogens in stool, urine, or blood samples using lateral flow assays or chemiluminescent platforms. Monoclonal anti-O157:H7 antibodies are pivotal in outbreak surveillance, reducing false positives in food safety testing.

• Therapeutic Development

Neutralizing antibodies against Stx toxins prevent endothelial injury in HUS, while anti-adhesin antibodies reduce UPEC biofilm formation in recurrent UTIs. Clinical trials highlight their potential as adjuncts to antibiotics in sepsis management.

• Vaccine Research

Antibodies targeting conserved epitopes on flagellin or outer membrane proteins (e.g., FliC, OmpA) facilitate vaccine efficacy studies by quantifying immunogenicity in preclinical models.

• Mechanistic Studies

Neutralizing antibodies are used to dissect bacterial adherence, toxin internalization, and immune evasion pathways, supporting the development of virulence inhibitors.

Our Anti- E. coli Neutralizing Antibodies

Creative Biolabs' E. coli specific antibodies are engineered to target conserved epitopes with minimal cross-reactivity:

- Anti-LPS Antibodies: High-affinity IgG/IgM clones specific to O-antigen serotypes (e.g., O157, O104) enable rapid serotyping and toxin neutralization in diarrheal diseases.

- Anti-Toxin Antibodies: Monoclonal antibodies against Shiga toxin (Stx1/Stx2) and heat-stable enterotoxin (STa) block receptor binding, preventing epithelial damage and systemic complications.

- Anti-Adhesin Antibodies: Neutralizing antibodies targeting FimH (type 1 pili) or PapG (P fimbriae) inhibit UPEC colonization in the urinary tract.

Validated in ELISA, flow cytometry, and neutralization assays, these antibodies exhibit batch-to-batch consistency for diagnostic kit development and therapeutic candidate screening.

Creative Biolabs offers E. coli specific Neutra™ antibody products combining unmatched specificity, affinity, and scalability to advance your therapeutic and diagnostic research projects. Our portfolio includes ready-to-use kits for ELISA, immunohistochemistry, and functional neutralization assays.

Contact our team today to discuss custom antibody development, bulk orders, or technical support.

REFERENCES

1. Terlizzi, Maria E., Giorgio Gribaudo, and Massimo E. Maffei. "UroPathogenic Escherichia coli (UPEC) infections: virulence factors, bladder responses, antibiotic, and non-antibiotic antimicrobial strategies." Frontiers in microbiology 8 (2017): 1566. https://doi.org/10.3389/fmicb.2017.01566
2. Abreu, Afonso G., and Angela S. Barbosa. "How Escherichia coli circumvent complement-mediated killing." Frontiers in immunology 8 (2017): 452. https://doi.org/10.3389/fimmu.2017.00452
3. Distributed under Open Access license CC BY 4.0, without modification.